| Bioactivity | SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is druglike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect[1]. |
| Target | IC50: 57 μM (nsp13 ssDNA+ ATPase) |
| Invitro | SARS-CoV-2 nsp13-IN-4 (C4 (d)) inhibits the ssDNA+ ATPase activity and the ssDNA− ATPase activity of nsp13 with IC50 values of 57 μM and 240 μM, respectively[1]. |
| Name | SARS-CoV-2 nsp13-IN-4 |
| CAS | 923140-39-0 |
| Formula | C20H15BrN4O |
| Molar Mass | 407.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Aliakbar Khalili Yazdi, et al. Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. ACS Infect Dis. 2022 Jul 13. |
SARS-CoV-2 nsp13-IN-4
CAS: 923140-39-0 F: C20H15BrN4O W: 407.26
SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibitthe ssDNA+ A
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.